Europe
The U.S. Food and Drug Administration has four distinct approaches to speeding the drug approval process. Several of today’s announcements had one or more of these designations.
In addition to coming sooner than expected, the results are even better than expected. The trial hit all primary efficacy endpoints.
Finerenone is an oral, non-steroidal selective mineralocorticoid receptor antagonist (MRA).
There are similarities between the two COVID-19 vaccine candidates, and a few differences. Here’s a look.
Late Friday, the regulatory agency rejected the medication of sutimlimab due to deficiencies from a pre-license inspection of a third-party manufacturing facility.
Sanofi was formally charged over Depakine, its epilepsy drug, for not taking action when they first discovered the fetal risks when taken by pregnant women.
The BioNTech scientist said his vaccine can “bash the virus over the head”.
Synairgen announced today that its data from the SG016 trial was published in the journal The Lancet Respiratory Medicine. The trial, which included 101 hospitalized COVID-19 patients, looked at SNG001 as a potential treatment.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
This morning, the company announced it bolstered its own gene therapy activities with the acquisition of Handl Therapeutics BV, a rapidly growing and transformative gene therapy company.
PRESS RELEASES